Single‐dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies

K. C. Yeh, A.N. Chremos, J H Lin, M.L. Constanzer, S. M. Kanovsky, H. Hücker, Joseph M. Antonello, Peter H. Vlasses, J. R. Ryan, Robert L. Williams

Biopharmaceutics & Drug Disposition · 1987 · 48 citations · 16 references

Concepts

Abstract

Pharmacokinetics and bioavailability of famotidine, a new H2-receptor antagonist, were investigated in healthy subjects in five clinical studies. Linear pharmacokinetics were observed following either intravenous or oral administration. Plasma clearance averaged 463 ml min-1. Renal clearance averaged 310 ml min-1, which exceeded the glomerular filtration rate. Renal excretion was the major route of elimination. Urinary recovery of unchanged drug following intravenous administration was about 67 per cent. Famotidine plasma half-life was approximately 2.6 h. Oral absorption was incomplete. The bioavailability averaged 43 per cent of the dose.

References

16